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Introduction
The combination of tumor necrosis factor antagonists (anti-TNF) and thiopurines (combination therapy) is more effective than monotherapy with either of these drugs in patients with Crohn's disease and ulcerative colitis. 1, 2 This association is increasingly recommended in patients with inflammatory bowel disease (IBD). 3, 4 However, the use of thiopurines and anti-TNFs is associated with adverse effects, notably infections and malignancies. 5, 6 Several studies have shown an increased risk of serious and opportunistic infections in patients treated with anti-TNFs or thiopurines as monotherapy for IBD. [7] [8] [9] [10] It is unclear if this risk is higher with antiTNFs than with thiopurines, and if combination therapy carries a higher risk than monotherapy. Meta-analyses and pooled analyses of randomized controlled trials do not suggest an increased risk of serious infections with combination therapy, [11] [12] [13] while an increased risk of opportunistic infections has been reported compared to anti-TNF monotherapy. 14 Differences in site and pathogen specific infections may explain the inconsistency of previous findings. Most importantly, these results are based on limited samples of selected patients. They may lack sufficient power to detect risk differences and may not apply to the general population of unselected patients. Therefore, large population-based studies are needed to better define the benefit-risk balance of these drugs.
The aim of this population-based study was to compare the risks of serious and opportunistic infections between thiopurine monotherapy, anti-TNF monotherapy, and combination therapy in a large sample of patients with IBD.
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Methods
Data sources
This cohort study was based on the French National Health Insurance database (Système National d'Information Inter-Régimes de l'Assurance Maladie, SNIIRAM), 15 which covers 95% of the French population with different insurance schemes based on employment situation. The general health insurance scheme covers employees in the industry, business and service sectors, public service employees and students,
accounting for approximately 88% of the French population. Due to data availability and quality, only individuals insured by the general scheme were considered.
Excluded insurance schemes cover specific professions and do not depend on comorbidities or medical conditions.
The SNIIRAM provides individual data on all drug reimbursements and outpatient medical care prescribed by healthcare professionals as well as individuals' status with respect to full reimbursement of care for severe long-term diseases (LTD), 15 including Crohn's disease and ulcerative colitis. Using a unique anonymous identifier, information from the SNIIRAM is linked to the French national hospital discharge database which provides individual medical information since 2006 on all hospital admissions in France, including discharge diagnoses (International Classification of Diseases, 10th edition ) and medical procedures performed. These databases have been used previously for large pharmacoepidemiological studies. [16] [17] [18] [19] [20] This study was approved by the French Data Protection Authority. All data used in this study only contained anonymous patient records. accounted for incident cases of IBD. This cohort has been extensively described elsewhere. 18, 20 Patients with HIV infection, congenital immunodeficiency, organ transplantation, and incident patients with a concomitant diagnosis of serious infection at the date of IBD diagnosis were excluded.
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Follow-up
Date of inclusion in the cohort was January 1, 2009 for prevalent cases and the date of IBD diagnosis for incident cases. Considering that IBD therapeutic management may be different after occurrence of cancer and that chemotherapy may lead to M A N U S C R I P T A C C E P T E D 
Drug exposure
In France, infliximab and adalimumab are dispensed in hospitals or private clinics.
Adalimumab and thiopurines are dispensed by pharmacies for one month. 22 Patients who received infliximab were considered exposed for two months following the infusion, those who received adalimumab or thiopurines were considered exposed for one month following delivery. Drug exposures were assumed to start the day of the drug infusion or delivery. Combination therapy was defined as concomitant exposure to anti-TNFs and thiopurines. During follow-up, patients could be exposed successively to different treatment sequences and could therefore contribute to more than one group of drug exposure. Treatment withdrawal was defined by a period of at least two months, after the last day of exposure, without any new treatment delivery.
Outcomes
Study outcome was any serious infection, defined as a diagnosis of infection requiring hospitalization (related ICD-10 codes as primary diagnosis). Within this database, the diagnoses of infection requiring hospitalization and the type of infection have been shown to be accurate in 97% and 98% of the cases, respectively.
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Serious infections were classified according to infection sites. These included pulmonary; gastrointestinal; skin; urinary tract; ear, nose and throat (ENT); M A N U S C R I P T A C C E P T E D Analyses were performed using SAS (version 9.4) statistical software (SAS Institute).
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Results
Characteristics of the cohort months preceding cohort entry in 4.3%. These characteristics differed according to subsequent treatment exposure during follow-up (Table 1) . Patients unexposed to thiopurines and anti-TNFs had a mean age of 47.8 years; a majority of them had a longstanding, uncomplicated ulcerative colitis. Those exposed to thiopurines and/or anti-TNFs, were mostly younger than 40 years and recently diagnosed with Crohn's disease, and had substantial rates of IBD-related hospitalization or surgery at cohort entry.
Incidence of serious and opportunistic infections
Overall, 8561 serious infections and 674 opportunistic infections occurred, resulting in incidence rates of 9.4 and 0.8 per 1000 PY, respectively.
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Overall incidence rates of serious infections ranged from 8.4 per 1000 PY in patients unexposed to thiopurines and anti-TNFs to 10.5, 18.9, and 22.4 per 1000 PY in those exposed to thiopurine monotherapy, anti-TNF monotherapy, and combination therapy, respectively (Table 2) 
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Risk of opportunistic infections according to IBD treatment exposure
Patients exposed to combination therapy, anti-TNF monotherapy or thiopurine monotherapy had increased risks of opportunistic infections compared to patients unexposed to thiopurines and anti-TNFs (Supplementary table 6 ).
Combination therapy was associated with an increased risk of opportunistic infections compared to anti-TNF monotherapy overall (HR, 1.96; 95% CI, 1.32-2.91) ( Table 4 ).
This increased risk concerned viral, mycobacterial, and bacterial infections.
Combination therapy was also associated with an increased risk of opportunistic infections compared to thiopurine monotherapy, overall (HR, 2.11; 95% CI, 1.45-3.08), and for mycobacterial and bacterial infections.
Anti-TNF monotherapy was not associated with a significantly different risk of opportunistic infections compared to thiopurine monotherapy overall (HR, 1.08; 95% CI, 0.83-1.40). However, the risks of mycobacterial and bacterial infections were higher with anti-TNF monotherapy than with thiopurine monotherapy (HR, 1.98; 95% M A N U S C R I P T 
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Subgroup and sensitivity analyses
Incidence rates of serious and opportunistic infections were increased in patients aged 65 or more, compared to younger patients. Specifically, the annual incidence of serious infection in patients aged 65 or more, exposed to anti-TNFs, either in monotherapy or combination therapy, was approximately 5% (Table 5 ). However, hazard ratios were similar in patients younger and older than 65 years (Table 6 ).
Results were consistent across IBD subtype, and were unchanged after exclusion of gastrointestinal and mycobacterial infections. The various sensitivity analyses yielded consistent results (Supplementary table 7) .
Discussion
Based on a large population-based, nationwide cohort study, our findings suggest that among patients with IBD, the risks of serious and opportunistic infections are higher with combination therapy than with thiopurine monotherapy or anti-TNF monotherapy. In addition, the risks of serious infections and of mycobacterial as well as opportunistic bacterial infections are increased with anti-TNF monotherapy compared to thiopurine monotherapy. Yet, the risk of opportunistic infections with anti-TNF monotherapy does not differ from that of thiopurine monotherapy, due to a lower risk of opportunistic viral infections with anti-TNFs than with thiopurines.
Observational studies have provided conflicting results on the risk of infection related to anti-TNFs. [8] [9] [10] Such an inconsistency is likely to be related to differences in exposure definitions, comparators, and study populations considered. Indeed, most 9 and they may have an impact on treatment modification and occurrence of infection. To our knowledge, the present study, based on a large and unselected population, is the first to provide two-by-two comparisons of the risk of infections between the various immunosuppressive-based IBD treatment regimens, adjusting for both fixed and time-dependent covariates including IBD activity and exposure to corticosteroids.
We found that combination therapy and anti-TNF monotherapy were associated with an increased risk of almost all site-specific serious infections compared to thiopurine monotherapy. In the recent Danish study, an increased risk of serious infection was reported with anti-TNFs, although it was only statistically significant for skin
infections. 8 Our findings suggest that anti-TNFs may be associated with an increased risk of infections, irrespective of the infection site, which is consistent with the fact that TNF has a central role in host response to infection, regardless of its site.
While several observational studies assessed the risk of opportunistic infections in patients with rheumatoid arthritis, very few included patients with IBD. 14, 26, 27 Although the definition of opportunistic infections may differ across studies, the rates of opportunistic infections reported in our study are in the range of those reported previously. 27, 28 We found that exposure to anti-TNFs, either in combination or monotherapy was associated with increased risks of opportunistic bacterial and mycobacterial infections compared to thiopurine monotherapy. This is consistent with previous studies reporting increased risks of bacterial and mycobacterial infections related to anti-TNFs. 29, 30 Moreover, combination therapy was associated with increased risks of opportunistic bacterial and mycobacterial infections compared to anti-TNF monotherapy, suggesting that the risks of opportunistic bacterial and mycobacterial infections are additionally increased by adding thiopurines to antiTNFs, as reported in a meta-analysis of clinical trials. 31 The situation was different regarding opportunistic viral infections. Indeed, while combination therapy was associated with an increased risk of opportunistic viral infections compared to anti-TNF monotherapy, no difference was found compared to thiopurine monotherapy as a result of a lower risk with anti-TNFs than with thiopurines. This suggests that the risk of opportunistic viral infections under combination therapy is driven by thiopurines. Consistently, previous studies showed that thiopurines increase the risk of viral infections.
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Age is a major risk factor of serious and opportunistic infections. Finally, we assessed time dependent confounding variables such as IBD activity and corticosteroids exposure.
Some limitations should be noted. Until now, there has been no validation study of the ICD codes related to IBD in the SNIIRAM database. However, a descriptive study on the same cohort 18 reported treatment exposure, hospitalization, and surgery rates similar to current standard of care and incidence rates in the range of those reported in other populations. 32 Although identification of infection was based on discharge diagnosis only, the validity of our outcomes was recently assessed, with more than 95% accuracy of recorded cases and type of infections. 23 In addition, incidence rates of serious infections in patients exposed to anti-TNFs reported in our study are M A N U S C R I P T 
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Appendix: Methods
Under the assumption of no unmeasured confounders, we used marginal structural models to estimate causal effects of thiopurines and anti-TNFs on the risk of serious infections. 1 These models, adjusted for time-dependent covariates with inverse probability treatment weights, are appropriate in the presence of time-dependent covariates (such as exposure to corticosteroids and IBD activity) that might be associated with both prescription of thiopurines or anti-TNFs and outcomes (time-dependent confounders) and could also be affected by past exposure to thiopurines and anti-TNFs.
The conditional probability of receiving observed treatment was estimated using multinomial logistic regression with generalized logit link. Covariates included were the baseline and time-dependent covariates (listed in Table 1 ) and past treatment history. Weights from the exposure selection model were calculated as follows: the numerator was the probability of receiving the treatment actually received after treatment modification conditional on baseline covariates and past treatment history. The denominator was the predicted probability of receiving the treatment actually received after treatment modification conditional on baseline covariates, past treatment history and time-varying covariates. To adjust for potential selection bias from loss to follow-up, we similarly modeled the propensity to be censored. Binary logistic regression was used for the censoring model. Weights from the censoring model were calculated as follows: the numerator was the probability of being censored conditional on baseline covariates and past treatment history. The denominator was the predicted probability of being censored conditional on baseline covariates, past treatment history and time-varying covariates. The stabilized weights were the product of the weights from the exposure selection and the censoring models, updated at each time interval. After calculation, the weights were truncated at 1st and 99 th percentiles to minimize the impact of extreme weights and improve precision. 2, 3 In the main analysis, stabilized weights using inverse probability of treatment and inverse probability of censoring were calculated at each treatment modification, since treatment assignment was continuously recorded rather than during scheduled follow-up visits. It may also provide a precise estimation of drug exposure, notably treatment introduction, while the increased risk of serious infections associated with anti-TNFs was mostly observed right after treatment introduction. 4 In a complementary analysis, we discretized the time scale on periods of one month for the estimation of the weights and results were shown to be consistent. After truncation at the 1 st percentile (0.43) and 99 th percentile (3.43), Mean (SD) of the weights were 1.02 (0.39). There was no tendency for the mean to deviate from 1 after a long period of follow-up. The outcome analysis model was adjusted for baseline covariates. Robust variance estimators were used to estimate conservative 95% confidence intervals. 
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